Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur in approximately 5% of non-small cell lung cancers (NSCLCs), in which they identify a distinct subtype of lung tumor that shows exquisite sensitivity to therapy with ALK tyrosine kinase-inhibitors (ALK-TKIs) (1).

Despite durable responses to the first-generation ALK-TKI crizotinib, the development of acquired resistance occurs in virtually all patients (2). From a biological standpoint, resistance to crizotinib develops either by ‘on target’ (ALK secondary mutations in the tyrosine kinase domain or ALK amplification) or ‘off target’ mechanisms (activation of signaling pathways other than ALK) (3). The novel second-generation ALK-TKI brigatinib has shown preclinical activity against a wide spectrum of ALK secondary mutations associated with resistance to crizotinib, and consistently, it proved to be clinically effective in crizotinib-refractory patients (4–6). Against this background, in September 2018, Camidge and colleagues reported in the New England Journal of Medicine the eagerly awaited results of the ‘ALTA-1L’ trial, which compared brigatinib with crizotinib in ALK-positive advanced NSCLC (7).

**Study overview**

‘ALTA-1L’ is a multicenter, randomized, open-label, phase 3 trial that allocated 275 patients with ALK-TKI naïve ALK-positive advanced NSCLC in a 1:1 ratio to either brigatinib 180 mg once daily (after a 7 days lead-in phase at 90 mg; N=137) or crizotinib 250 mg twice daily (N=138) (7). Crossover to brigatinib was allowed for patients in the crizotinib arm, upon confirmation of disease progression by blinded independent review assessment. The primary endpoint of the study was progression-free survival (PFS), while secondary endpoints included objective response rate (ORR), intracranial ORR (IORR), intracranial PFS, and overall survival. The first pre-specified interim analysis was performed at 50% of expected events (99/198). With a median follow-up of 11.0 months in the brigatinib group and 9.3 months in the crizotinib group, blinded independent review-assessed PFS was significantly longer for brigatinib [median PFS not reached versus 9.8 months (95% CI, 9.0–12.9 months), respectively], with an estimated 12-month progression-free rate of 67% (95% CI, 56–75%) versus 43% (95%, CI, 32–53%), respectively, and a hazard ratio (HR) for progression or death of 0.49 in favor of brigatinib [(95% CI, 0.33–0.74%), P<0.001]. The subgroup analysis showed that brigatinib was superior to crizotinib across several clinical characteristics, including performance status (0 or 1), presence of brain metastases (BMs) at baseline, and prior exposure to chemotherapy for advanced disease (the study allowed patients pretreated...
with no more than one prior systemic anticancer therapy). Of note, the HR for progression or death in favor of brigatinib was 0.35 (95% CI, 0.14–0.85%) and 0.55 (95% CI, 0.34–0.88%) in patients who had or had not received prior chemotherapy, respectively. With regard to secondary endpoints, brigatinib yielded a higher ORR by blinded independent review in the intention-to-treat population, being 71% (95% CI, 62–78%) for brigatinib and 60% (95% CI, 51–68%) for crizotinib. In addition, response to treatment was more durable in the brigatinib arm than in the crizotinib arm [median duration of response not reached versus 11.1 months (95% CI, 9.2–not reached months), respectively]. However, the most striking difference between the two treatment arms was observed in the subgroup of patients with BMs at baseline. Overall, 90 patients out of 275 had BMs (32.7%) by blinded independent review, of whom 18/43 (41.9%) and 21/47 (44.7%) had measurable BMs according to RECIST v1.1 in the brigatinib and crizotinib groups, respectively. Of note, in this subgroup the confirmed IORR was 78% (95% CI, 52–94%) for brigatinib and 29% (95% CI, 11–52%) for crizotinib. A similarly higher difference in activity against central nervous system (CNS) disease was observed in the overall population with BMs, with a confirmed IORR of 67% (95% CI, 51–81%) in the brigatinib arm as compared to 17% (95% CI, 8–31%) in the crizotinib arm. Interestingly, when the authors carried out an exploratory competing-risks analysis of intracranial or systemic disease progression and death, they found that the cause-specific HR for time to progression of intracranial disease was 0.30 (95% CI, 0.15–0.60%) in favor of brigatinib. Overall survival data were not mature at the time of the analysis, 1-year rate of survival being 85% (95% CI, 76–91%) for brigatinib and 86% (95% CI, 77–91%) for crizotinib. No unexpected toxicities occurred during the trial, and no treatment-related deaths were reported. However, some significant differences in toxicities were noted between the two study arms: regardless of the severity, increased blood creatine kinase level, cough, hypertension and increased lipase/amylase levels were more common in the brigatinib arm, while gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), peripheral edema, increased alanine aminotransferase level, decreased appetite, photopsia, dysgeusia, and visual impairment were more common in patients receiving crizotinib. Grade 3 or higher interstitial lung disease or pneumonitis occurred in 3% of patients randomized to brigatinib and the rate of any grade interstitial lung disease or pneumonitis was 3% in patients who crossed over from crizotinib to brigatinib.

**Place in therapy**

Although ‘ALTA-1L’ has clearly shown that brigatinib improves PFS compared to crizotinib in ALK-TKI naïve ALK-positive NSCLC patients, the extent of this benefit remains to be determined as the follow-up is still immature. Brigatinib has previously demonstrated to be effective at progression on crizotinib, with some signs of antitumor activity also when administered after the second-generation ALK-inhibitor alectinib (5,6,8). In the latest update of the ‘ALTA’ phase 2 trial of crizotinib-refractory patients, brigatinib has shown an ORR of 56% with a remarkable median PFS of 16.7 months, which emerges as the longest PFS of any ALK inhibitor to be reported for patients who have progressed on crizotinib (6). However, whether this highest-ranking position in the post-crizotinib setting will translate into a first-ranking benefit in ALK-TKI naïve patients is yet to be determined. Preclinical data have shown that brigatinib has the broadest in vitro coverage against secondary ALK resistance mutations compared to the other clinically available second-generation ALK inhibitors, namely alectinib and ceritinib (9,10). If expectations will be met, it can be argued that moving brigatinib in the first-line setting may significantly delay the emergence of resistance to treatment. However, the recent phase 3 ‘ALEX’ trial has established alectinib as the new preferred first-line option for patients with ALK-positive advanced NSCLC (11,12). In ‘ALEX’, alectinib excelled over crizotinib in term of median PFS [34.8 versus 10.9 months, respectively; HR =0.43 months (95% CI, 0.32–0.58 months)], and also provided evidence for a greater intracranial activity [median PFS in patients with BMs was 27.7 versus 7.4 months, respectively; HR =0.35 months (95% CI, 0.22–0.56 months)]. Therefore, data from ‘ALTA-1L’ add to the current standard of care as they expand to brigatinib the treatment options for ALK-TKI naïve ALK-positive NSCLCs. Despite a shorter follow-up, the early ‘ALTA-1L’ results for brigatinib as compared with crizotinib appear similar to clinical outcomes from the ‘ALEX’ trial (Table 1). However, at present time there are no data favoring the use of brigatinib over alectinib as first-line treatment or vice versa. As alectinib has already moved into the up-front setting, the most important question that we need to address is what are the most active treatments for patients who progress on alectinib. In a recent retrospective study of 22 alectinib-refractory ALK-positive patients treated with brigatinib, Lin et al. (2019)
reported an ORR of 16.7% (3/18 patients with baseline measurable disease) and a median PFS of 4.4 months (8). This study showed that clinical outcomes on brigatinib following alectinib are considerably lower as compared to the crizotinib-refractory setting, which is not surprising given the similar ALK inhibitory potency and activity against CNS disease of alectinib and brigatinib. Likewise, the ‘ASCEND-9’ trial evaluated the clinical activity of another clinically available second-generation ALK-TKI such as ceritinib in patients who had progressed on alectinib. Among 20 alectinib-pretreated patients enrolled in this study, the ORR with ceritinib was 25%, and median PFS was dismal, being only 3.7 months (13). However, these data also indicate that, according to the mechanism of resistance, there might be room for brigatinib or ceritinib in a very selected subset of alectinib-refractory patients. We know that the presence of specific ALK resistance mutations affect the clinical sensitivity to other second-generation ALK-TKIs such as ceritinib in patients who had progressed on alectinib. Among 20 alectinib-pretreated patients enrolled in this study, the ORR with ceritinib was 25%, and median PFS was dismal, being only 3.7 months (13). However, these data also indicate that, according to the mechanism of resistance, there might be room for brigatinib or ceritinib in a very selected subset of alectinib-refractory patients.

Future directions

In ‘ALTA-1L’, brigatinib demonstrated superior efficacy compared with crizotinib in terms of both systemic and intracranial disease. This trial establishes brigatinib as a novel first-line option for ALK-TKI naïve ALK-positive NSCLC, along with alectinib. Having said that, the landscape of treatment of ALK-positive NSCLC is still evolving and several novel ALK-TKIs are under preclinical and clinical development, including, but not limited to, ensartinib, entrectinib and lorlatinib (15). Particularly, lorlatinib is a highly potent, selective ALK inhibitor that is able to surpass the blood-brain barrier and to be operate against most known ALK resistance mutations developing after exposure to crizotinib and second-generation ALK inhibitors, including G1202R (14). Consistently, in a phase 2 trial lorlatinib has recently demonstrated a meaningful overall and intracranial activity both in ALK-TKI naïve patients with ALK-positive NSCLC, as well as in those who had progressed on crizotinib and second-generation ALK inhibitors (16). Importantly, antitumor activity was seen across a range of ALK resistance mutations, including G1202R and G1202del, and in the group of patients pretreated with ≥1 ALK-TKIs the greatest
benefit was observed in patients who had been documented with ALK resistance mutations by either plasma or tissue genotyping (17). More importantly, and not surprisingly, the magnitude of the clinical benefit from lorlatinib was greater in ALK-TKI naïve patients. These data indicate that lorlatinib might provide an effective therapeutic first-line option, which is the rationale of the currently ongoing phase 3 ‘CROWN’ trial (NCT03052608) comparing lorlatinib versus crizotinib in treatment naïve ALK-positive NSCLCs.

As more treatment options are becoming available for these patients and the optimal sequence is still unclear, the US National Cancer Institute (NCI) has sponsored a biomarker-driven study which will help us to understand how to optimize patient selection for ALK-TKIs. The NCI-NRG ALK Master Protocol (NCT03737994) is a phase 2 trial designed for patients with advanced ALK-positive NSCLC, in which the different mutations will direct the given treatment and sequence (Figure 1). Hopefully, this study will lead us to a more comprehensive understanding of the proper management of these patients.

**Acknowledgements**

None.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

**References**


